AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / October 11, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company's latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815803/neurology-seminar-cns-3 . The presentation will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Image Attachments
Johan Sandin CSO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/667525/AlzeCure-Presents-at-Redeye-Neurology-CNS-Seminar-on-October-13
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AI and Cybersecurity Leader, SecureAuth, Appoints Geoffrey Mattson to Help Enterprises Secure Complex Human, Machine, and AI-agent Identities10.12.2025 17:30:00 CET | Press release
IRVINE, CALIFORNIA / ACCESS Newswire / December 10, 2025 / SecureAuth, a leader in AI-driven identity security, today announced the appointment of Geoffrey Mattson as Chief Executive Officer. Mattson's appointment marks the beginning of the company's next phase of growth as enterprises confront a rapid rise in AI agents with real authority, a shift that is increasing the complexity of business relationships and driving urgent demand for modern identity security. The Board of Directors thanks outgoing CEO Joseph Dhanapal, who will remain as a strategic advisor. During his tenure, SecureAuth invested heavily in creating a next generation security platform, featuring our market leading, AI-driven risk engine. With this platform in place, SecureAuth is positioned to capture accelerating demand for identity and access management as agentic AI transforms identity from a static access check into a dynamic control plane for managing complex human, machine, and AI-driven relationships. Mattson
Nasdaq Verafin Joins Global Anti-Scam Alliance10.12.2025 15:00:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / December 10, 2025 / The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems. Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime. "Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We a
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline10.12.2025 14:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / December 10, 2025 / Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, is future-proofing organizations with specialized translation services in the wake of the recent November 2025 ISO 20022 deadline. A major turning point for the financial industry, SWIFT now requires banks to move their cross-border payment messages to ISO 20022. As a result, treasury teams are already seeing differences in how their banks send and receive payment information. Adapting to these changes will require a strategic approach to modernizing systems and processes. ISO 20022 replaces a patchwork of older standards with a single approach to structuring payment data. The new universal standard is designed to reduce confusion across markets, improve data quality, and support the level of transparency that regulators around the globe now expect. Moving to ISO 20022 payments takes time and strategic vision, especially when legacy
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections9.12.2025 15:00:00 CET | Press release
New survey of 4,000 parents and children in the U.S. and Australia reveals sharp generational divides in support, fears, mental health expectations, and belief in government enforcement. WASHINGTON, DC / ACCESS Newswire / December 9, 2025 / The Family Online Safety Institute (FOSI) released new research today examining how parents and children in the United States and Australia view social media bans for anyone under 16. The findings reveal strong parental support for such bans, in contrast with widespread concern from children who fear losing friendships and support systems that exist primarily online. The research arrives as Australia implements a national under 16 social media ban, placing global attention on how the policy will affect youth and their families. FOSI's study surveyed 4,000 parents and children ages 10 to 17 to understand how both groups feel about restrictions, enforcement, and the broader impact of social media on daily life. Support for the Ban: Parents vs Children
Techmer PM Joins Formerra's Portfolio in North America9.12.2025 15:00:00 CET | Press release
Formerra will distribute Techmer PM color masterbatches, high-performance additives, and pre-colored compounds across the U.S., Canada, and Mexico. ROMEOVILLE, ILLINOIS / ACCESS Newswire / December 9, 2025 / Formerra, a leader in performance materials distribution, today announced the addition of Techmer PM color masterbatches, high-performance additives, and pre-colored compounds to its expansive portfolio of materials. With this partnership, Formerra advances its application-specific lineup, aligning its material portfolio to customers' evolving needs across North America. A U.S.-based plastics compounder, Techmer PM specializes in value-added color and additive masterbatches and engineered compounds for high-performance plastics and fibers. These products are used in various industries such as medical, automotive, packaging, and consumer goods applications. Techmer PM has consistently invested in its optical and color capabilities, including the recent acquisition of OptiColor Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom